Briacell Therapeutics Corp is gaining traction on the TSX, reflecting positive investor sentiment.
Briacell Therapeutics Corp (BCT.TO) is rising today, with shares up by 4.25% to CA$4.91. This movement comes amid significant developments in the company's clinical pipeline and recent financial activities that have captured investor interest.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$41.93M
52W high
$20.40
52W low
$3.68
1W change
-3.09%
Beta
1.52
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 324.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+324.6% Upside
Current Price
C$4.71
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
62.4%
Annualized
90-Day Vol
83.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.94
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.44 | C$3.58 – C$5.50 |
| 60 trading days | C$4.18 | C$3.08 – C$5.67 |
| 90 trading days | C$3.94 | C$2.71 – C$5.72 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors may find Briacell's advancements in immunotherapy and recent funding initiatives promising indicators of future growth.
Briacell's Market Cap Reaches CA$41.9 Million
Advertisement
With a market cap of CA$41.9 million, Briacell Therapeutics Corp is positioning itself as a notable player in the biotech sector, particularly in cancer immunotherapy.
Bull case
Briacell has recently completed the clinical supplies for its Bria-PROS+ immunotherapy candidate and secured a $2 million grant from the U.S. National Cancer Institute. This funding could boost the company's research capabilities and speed up its clinical trials. Additionally, the company has raised about $30 million through a public offering of 5,366,726 units, providing the necessary capital to support ongoing projects. These developments could lead to breakthroughs in cancer treatment.
Bear case
Despite today's gains, Briacell faces challenges. The company has struggled with consistent profitability, and the inherent risks in biotech development could make it difficult to maintain investor confidence. Stakeholders will need to watch closely as the company navigates these hurdles.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
